Emmaus Life Sciences, Inc. (EMMA)
Upgrades & Downgrades
Latest EMMA news
Emmaus Life Sciences CEO Dr Yutaka Niihara highly praised by the Indian government for developing En...
19 December 2022
Emmaus Life Sciences Inc (OTCQX:EMMA) revealed that the company's CEO Dr Yutaka Niihara was feted at an event held on December 16, 2022, at the World Trade Center in Mumbai, India, by Indian Minister ...
Emmaus Life Sciences gets marketing authorization from Kuwaiti authorities for Endari
7 December 2022
Emmaus Life Sciences Inc (OTCQX:EMMA) announced that the Kuwaiti Ministry of Health has granted marketing authorization for the commercial distribution and sale of its Endari product in the Gulf count...
Emmaus Life Sciences receives first major purchase order in Saudi Arabia
17 November 2022
Emmaus Life Sciences Inc said it has received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, where its drug Endari is available on an early access basis. The Torra...
Emmaus Life Sciences says Q3 revenue boosted by sales of Endari in the United Arab Emirates
15 November 2022
Emmaus Life Sciences Inc (OTCQX:EMMA) has reported net revenue of $4.9 million for the third quarter of 2022, nearly 15% higher than the $4.3 million recorded in the second quarter, boosted primarily ...
Emmaus Life Sciences announces collaboration with Kier (Junior) Spates to educate and support patien...
28 September 2022
Emmaus Life Sciences Inc (OTCQX:EMMA) said it is collaborating with Steve Harvey Morning Show cast member Kier (Junior) Spates to share Spates' personal experience using the company's prescription L-g...
Emmaus Life Sciences reports Q2 2022 net revenue of $4.3M after sales of Endari sickle cell disease ...
16 August 2022
Emmaus Life Sciences Inc (OTCQX:EMMA) has announced its financial results for the three and six months ended June 30, 2022, which received a fillip from the marketing approval in May of its sickle cel...
Emmaus Life Sciences says successfully expands market access to sickle cell treatment Endari in 1Q
13 May 2022
Emmaus Life Sciences Inc (OTCQX:EMMA) co-founder and CEO Dr Yutaka Niihara has told investors that the commercial-stage biopharmaceutical company successfully expanded market and patient access to sic...
Emmaus Life Sciences to Present at Investor Conferences in May
26 April 2022
TORRANCE, Calif. , April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today ann...
Emmaus Life Sciences launches full-service telehealth solution with online access to sickle cell tre...
11 April 2022
Emmaus Life Sciences Inc has announced that it has launched an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScript I...
Emmaus Life Sciences presents positive study data on Endari treatment in sickle cell patients
7 April 2022
Emmaus Life Sciences Inc (OTCQX:EMMA) has announced real-world data on the company's prescription-grade L-glutamine oral powder, Endari, in preventing acute complications from sickle cell disease and ...